Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 13/20 | 0.41 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.35 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.33 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.33 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 2/20 | 0.33 |
| ▸ | BRD2 | P25440 | 1/20 | 0.31 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4020887 | 0.88 | MAPK14 (0.41) | MAPK14MAPK11MAPK13MAPK12BRD4 | |
| SCHEMBL14019114 | 0.86 | MAPK14 (0.36) | MAPK14PDCD1LG2CD274MAPK11MAPK13 | |
| SCHEMBL4840495 | 0.86 | MAPK14 (0.41) | MAPK14MAPK11MAPK13MAPK12BRD4 | |
| SCHEMBL4845211 | 0.85 | MAPK14 (0.42) | MAPK14MAPK11MAPK13MAPK12BRD4 | |
| SCHEMBL4840514 | 0.84 | SCN9A (0.42) | MAPK14 | |
| SCHEMBL4841004 | 0.84 | MAPK14 (0.40) | MAPK14MAPK11BRD4MAPK8 | |
| SCHEMBL4841162 | 0.84 | MAPK14 (0.39) | MAPK14MAPK11BRD4 | |
| SCHEMBL4833744 | 0.84 | ALDH1A1 (0.44) | MAPK14MAPK11BRD4 | |
| SCHEMBL4837418 | 0.84 | MAPK14 (0.40) | MAPK14PDCD1LG2CD274MAPK11BRD4 | |
| SCHEMBL4839495 | 0.84 | MAPK14 (0.41) | MAPK14MAPK11BRD4MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7435731-B2 | Substituted pyrazolo[3,4-d]pyrimadines and methods of using the same | ROCHE PALO ALTO LLC (US) | 2008-10-14 | — | — | US | claimed |
| US-7435731-B2 | Substituted pyrazolo[3,4-d]pyrimadines and methods of using the same | ROCHE PALO ALTO LLC (US) | 2008-10-14 | — | — | US | disclosed |
| US-20050197340-A1 | Fused-pyrazolo pyrimidine and pyrazolo pyrimidinone derivatives and methods for using the same | ROCHE PALO ALTO LLC | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197340-A1 | Fused-pyrazolo pyrimidine and pyrazolo pyrimidinone derivatives and methods for using the same | MAP3K1, MAPK1, MAP3K8 | MAPK14 70/4885PDCD1LG2 3085/4885CD274 4008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.